|[April 22, 2014]
EOS® Imaging System Installed at Meijo Hospital in Japan
PARIS --(Business Wire)--
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI), the pioneer in
2D/3D orthopaedic medical imaging, today announced the installation of
the EOS® imaging system in Japan's leading spine medical center at Meijo
Hospital in Nagoya. The installation is one of the four installations of
EOS in Japan since the equipment has received market clearance.
Japanese adoption of the EOS system began in December 2013 with the
first installation at Niigata Spine Surgery Center (NSSC) following
regulatory approval by Japanese authorities. The current installation at
the Meijo Hospital, affiliated with the Nagoya University Hospital,
underscores the adoption of EOS by the best Japanese institutions for
spine surgery. Meijo Hospital has the highest volume of deformative
spine surgeries in Japan.
Professor Noriaki Kawakami, Director of Orthopedic Surgery at Meijo
Hospital, said, "Our hospital performs a vital role providing
community health services throughout Japan. The installation of EOS in
our facilities and throughout Japan is an important step in ensuring
that our patients have access to the most beneficial imaging technology
Mari Meynadier, CEO of EOS imaging, said, "We are happy to report
rapid adoption of the EOS system in Japan. The Meijo Hospital, one among
our four recent installations, demonstrates the positive results from
our ongoing market development strategy in the Asia-Pacific region. We
are confident that EOS adoption will continue in Japan and throughout
the region as other physicians see the value of our technology
demonstrated at these hospitals."
For further information about the Company or EOS®, the first full body,
low dose 2D/3D imaging system, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and
patented medical imaging system, based on technology that enabled George
Charpak to win the Nobel (News - Alert) Prize for Physics. The Company is authorized to
market the system in 32 countries, including the United States (FDA),
Japan, Canada, Australia and the European Union (EU). Backed by an
installed base of 75 sites and more than 400,000 imaging sessions, EOS®
benefits from worldwide recognition within the global medical community.
As of December 31, 2013 the Group posted 2013 consolidated revenue of
€15.2 million and employed 101 people including an R&D team of
38 engineers. The Group is based in Paris and holds four subsidiaries in
Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and
Frankfurt (Germany), and offices in Singapore. For further information,
please visit www.eos-imaging.com.
EOS imaging is listed on Compartment C of Euronext Paris
FR0011191766 - Ticker: EOSI
Next press release: revenue for
the 1st half of 2014, on July 22, 2014 (after
[ Back To TMCnet.com's Homepage ]